Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

The FDA approved a new Pfizer drug for hair loss in teens.

The study found two new mutations in a Chinese patient with severe biotinidase deficiency.

Temporal triangular alopecia is a non-scarring hair loss in children, often linked to other health conditions.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Putting thymidine dinucleotide on newborn mice's skin can delay and reduce skin cancer.

The report expanded knowledge of MBTPS1-related disorders by identifying new symptoms.

A 2-year-old boy was diagnosed with a rare genetic condition causing fragile hair, intellectual issues, and short stature.

Ritlecitinib works well and is safe for treating alopecia areata.

Trichorhinophalangeal syndrome causes hair, facial, and bone issues, with no specific treatment beyond gentle care.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

The new graft-holding solution is better at preserving hair grafts and reducing hair shedding after transplantation than the standard solution.

A gene mutation causes curly hair and hair loss in rats.

CTA is often mistaken for AA but doesn't respond to steroids and may require hair transplantation.

A 23-year-old man has a benign, non-progressive hair loss patch that doesn't respond to treatment but can be cosmetically treated.

Researchers created a cell line to study hair growth and found specific genes affected by dihydrotestosterone.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Trichothiodystrophy causes unusual hair and developmental issues.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.

A new compound was effective for imaging prostate cancer in rats.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.